DEF 14A: Capricor Therapeutics Seeks Stockholder Approval for 2025 Equity Incentive Plan and Director Elections

Capricor Therapeutics is soliciting proxies for its 2025 Annual Meeting of Stockholders, including proposals for director elections, ratification of the accounting firm, approval of the 2025 Equity Incentive Plan, and an advisory vote on executive compensation.

Summary

• Capricor Therapeutics is holding its Annual Meeting of Stockholders on May 22, 2025.
• Stockholders will vote on the election of eight directors, ratification of Rose, Snyder & Jacobs LLP as the independent accounting firm, approval of the 2025 Equity Incentive Plan, and an advisory vote on executive compensation.
• The board recommends voting for all director nominees, ratifying the accounting firm, approving the equity incentive plan, and approving executive compensation.
• The record date for voting is March 26, 2025, with 45,676,887 shares outstanding.
• The 2025 Equity Incentive Plan proposes authorizing 3,500,000 shares for issuance, with an annual increase of 5% of outstanding shares, commencing January 1, 2026 and ending January 1, 2035.
• The board believes the separation of the Executive Chairman and CEO roles reinforces board independence.
• The company has agreements with Nippon Shinyaku for commercialization and distribution of deramiocel in the United States, Japan, and potentially Europe.
• Nippon Shinyaku holds 7,090,351 shares, representing 14.8% ownership in Capricor Therapeutics.

Sentiment

Score: 7

Explanation: The document is largely factual and procedural, outlining proposals for stockholder voting. The positive sentiment stems from the company's growth strategy, partnerships, and commitment to corporate governance, balanced by the inherent risks and uncertainties of the biopharmaceutical industry.

Positives

• The board is committed to actively seeking highly qualified women and individuals from underrepresented minority groups to include in the pool from which new candidates are selected.
• The company has commercialization and distribution agreements with Nippon Shinyaku for deramiocel in the United States, Japan, and potentially Europe.
• The board believes the separation of the Executive Chairman and CEO roles reinforces board independence.

Negatives

• Earl M. (Duke) Collier Jr., J.D. informed the company of his decision not to stand for reelection to the Board at the Annual Meeting.

Risks

• The company faces operational risks, such as cybersecurity risks, as well as risks associated with the significant financial needs to operate its business.
• The company relies on the Board to review related party transactions on an ongoing basis to prevent conflicts of interest.

Future Outlook

The company anticipates potential additional development and sales-based milestone payments from Nippon Shinyaku for the US, Japan and Europe distribution agreements. The company forecasts granting options covering approximately 2.5 million shares of its common stock over the next year.

Industry Context

Capricor Therapeutics operates in the biopharmaceutical industry, focusing on the development of therapeutics for cardiovascular and other diseases. The company's partnerships and agreements with Nippon Shinyaku are significant for its commercialization strategy, aligning with the industry trend of collaborations for drug development and distribution.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes Abeona Therapeutics, Arcturus Therapeutics, Dyne Therapeutics, Edgewise Therapeutics, Editas Medicine, Fate Therapeutics, Lineage Cell Therapeutics, Sana Biotechnology, Solid Biosciences, and Wave Life Sciences.
• These companies are similar in terms of industry sector, stage of development, employee headcount, and market capitalization.
• The compensation levels for Capricor's named executive officers in 2024 generally reflected market competitive positioning compared to the peer group.

Management Changes

Corporate Governance

Related Party Transactions

• Capricor has entered into commercialization and distribution agreements with Nippon Shinyaku, a shareholder of the company, for deramiocel in the United States, Japan, and potentially Europe.
• On September 16, 2024, the Company entered into a Subscription Agreement with Nippon Shinyaku pursuant to which the Company agreed to issue and sell to Nippon Shinyaku in a private placement (the Private Placement), an aggregate of 2,798,507 shares of the common stock of the Company at a price per Share of $5.36, which was issued at a 20% premium to the 60-day volume-weighted average price, for an aggregate purchase price of approximately $15.0 million.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will impact the company's governance, executive compensation, and equity structure.
• Employees may be affected by the approval of the 2025 Equity Incentive Plan, which provides for equity-based compensation.
• The company's partnerships with Nippon Shinyaku impact its ability to commercialize and distribute its products, affecting its financial performance and growth potential.

Next Steps

• Stockholders to vote on proposals at the Annual Meeting on May 22, 2025.
• Finalization of a definitive agreement with Nippon Shinyaku for the commercialization and distribution of deramiocel in the European region by April 30, 2025.
• The company will evaluate the terms of the definitive agreement in accordance with ASC 606, Revenue from Contracts with Customers.
• The company will continue to develop and manufacture deramiocel for potential approval in the European region.
• The company will continue to monitor and manage risks associated with its business operations.
• The company will continue to review and assess the performance of the Board and committees of the Board at least annually.
• The company will continue to review and approve (or, if it deems appropriate, recommend to the Board for determination and approval) the compensation of our executive officers, senior management and non-employee directors, taking into consideration the individuals success in achieving his or her individual performance goals and objectives and the corporate performance goals and objectives deemed relevant to him or her, as established by the Compensation Committee, in addition to other factors.

Key Dates

Keywords

Equity Incentive Plan, Annual Meeting, Director Election, Proxy Statement, Capricor, Deramiocel, Nippon Shinyaku, Executive Compensation, Corporate Governance